Drug Profile
Molibresib - GlaxoSmithKline
Alternative Names: GSK'762; GSK-525762; GSK525762A; GSK525762C; IBET762Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Amides; Antineoplastics; Benzodiazepines; Small molecules; Triazoles
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Carcinoma; Haematological malignancies; Prostate cancer; Solid tumours
Most Recent Events
- 28 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 01 Mar 2022 GlaxoSmithKline terminates the phase II AMLM22/D1 trial for Acute myeloid leukaemia (In adults, In the elderly, In adolescents) in Australia (PO), due to termination of development of the candidate, prior to March 2022 (ACTRN12619000248167p)
- 17 Feb 2022 Discontinued - Phase-I/II for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, South Korea, France, Canada, Australia, United Kingdom (PO) (GSK pipeline, February 2022)